Evaluation of atorvastatin tablet as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad

Evaluation of atorvastatin tablet efficacy as an adjuvant treatment for patients with mild to moderate COVID-19 in Qaem Hospital, Mashhad: A double-blind randomized placebo controlled clinical trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200408046990N3

Enrollment

Registered

2020-07-16

Start date

2020-07-21

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 pneumonia. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: one atorvastatin 40mg tablet daily for two weeks. Intervention 2: Control group: placebo with same appearance of atorvastatin tablet one daily for 2 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Laboratory or clinical diagnosis of COVID-19 with admission indication age between 18-65 y sign of the written consent not concomitant use of kaletra or other PIs, cyclosporine, colchicine, ciproterone, danazol, gemfibrozil, potent CYP3A4 inhibitors or inducers like macrolides, CCBs, Azoles, rifampin, phenytoin not using statin before including in the study

Exclusion criteria

Exclusion criteria: history of allergy to statins pregnancy and lactation active liver disease or rise of LFT during study including in other studies start of PIs ADR occurrence e.g. rhabdomyolysis severe renal failure (GFR<30 ml/min) indication for intubation or ICU not being able to swallow medication

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: daily. Method of measurement: thermometer.;Clinical response to treatment (including improvement of cough, myalgia, headache, Olfactory and taste disorders). Timepoint: daily. Method of measurement: based on patients examination and interview.;Radiologic response. Timepoint: two weeks after treatment. Method of measurement: lung CT scan.;Laboratory response. Timepoint: weekly. Method of measurement: assessment of serum level of CRP and CBC diff.;Drug adverse reaction. Timepoint: daily. Method of measurement: patient file and interview.	—

Measure

Time frame

Fever. Timepoint: daily. Method of measurement: thermometer.;Clinical response to treatment (including improvement of cough, myalgia, headache, Olfactory and taste disorders). Timepoint: daily. Method of measurement: based on patients examination and interview.;Radiologic response. Timepoint: two weeks after treatment. Method of measurement: lung CT scan.;Laboratory response. Timepoint: weekly. Method of measurement: assessment of serum level of CRP and CBC diff.;Drug adverse reaction. Timepoint: daily. Method of measurement: patient file and interview.

—

Secondary

Measure	Time frame
Duration of hospitalization. Timepoint: end of the treatment. Method of measurement: patients' file.;Patients' clinical outcome. Timepoint: at the of the treatment. Method of measurement: patients' file.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSepideh Elyasi

Mashhad University of Medical Sciences

elyasis@mums.ac.ir+98 51 3180 1588

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026